{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T02:26:50Z","timestamp":1780453610697,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108003"],"award-info":[{"award-number":["82020108003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108003"],"award-info":[{"award-number":["82020108003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06428-5","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T09:57:12Z","timestamp":1748858232000},"page":"3309-3317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective cohort study of chimeric antigen receptor T-Cell therapy in follicular lymphoma patients with or without histological transformation"],"prefix":"10.1007","volume":"104","author":[{"given":"Jingjing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangyu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"issue":"20","key":"6428_CR1","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"issue":"10","key":"6428_CR2","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","volume":"4","author":"CJ Gallagher","year":"1986","unstructured":"Gallagher CJ, Gregory WM, Jones AE, Stansfeld AG, Richards MA, Dhaliwal HS et al (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 4(10):1470\u20131480. https:\/\/doi.org\/10.1200\/JCO.1986.4.10.1470","journal-title":"J Clin Oncol"},{"issue":"26","key":"6428_CR3","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","volume":"31","author":"BK Link","year":"2013","unstructured":"Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI et al (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of Iowa\/MayoClinic specialized program of research excellence molecular epidemiology resource. J Clin Oncol 31(26):3272\u20133278. https:\/\/doi.org\/10.1200\/JCO.2012.48.3990","journal-title":"J Clin Oncol"},{"issue":"4","key":"6428_CR4","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/bjh.12570","volume":"163","author":"M Ban-Hoefen","year":"2013","unstructured":"Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI et al (2013) Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 163(4):487\u2013495. https:\/\/doi.org\/10.1111\/bjh.12570","journal-title":"Br J Haematol"},{"issue":"7","key":"6428_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","volume":"14","author":"SJ van der Stegen","year":"2015","unstructured":"van der Stegen SJ, Hamieh M, Sadelain M (2015) The Pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Discov 14(7):499\u2013509. https:\/\/doi.org\/10.1038\/nrd4597","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"6428_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s10147-023-02334-w","volume":"28","author":"H Goto","year":"2023","unstructured":"Goto H, Kitawaki T, Fujii N, Kato K, Onishi Y, Fukuhara N et al (2023) Safety and efficacy of tisagenlecleucel in patients with relapsed or refractory B-cell lymphoma: the first real-world evidence in Japan. Int J Clin Oncol 28(6):816\u2013826. https:\/\/doi.org\/10.1007\/s10147-023-02334-w","journal-title":"Int J Clin Oncol"},{"issue":"22","key":"6428_CR7","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","volume":"4","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Di Blasi R, Kanoun S, Tessoulin B, Rossi C, D\u2019Aveni-Piney M et al (2020) Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma. Blood Adv 4(22):5607\u20135615. https:\/\/doi.org\/10.1182\/bloodadvances.2020003001","journal-title":"Blood Adv"},{"issue":"7","key":"6428_CR8","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ, Lymphoma Program Investigators at the University of Pennsylvania (2021) Five-Year outcomes for refractory B-Cell lymphomas with CAR T-Cell therapy. N Engl J Med 384(7):673\u2013674. https:\/\/doi.org\/10.1056\/NEJMc2030164","journal-title":"N Engl J Med"},{"issue":"10254","key":"6428_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J et al (2020) Lisocabtagene Maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839\u2013852. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"issue":"6","key":"6428_CR10","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood.2023021243","volume":"143","author":"SS Neelapu","year":"2024","unstructured":"Neelapu SS, Chavez JC, Sehgal AR, Epperla N, Ulrickson M, Bachy E et al (2024) Three-year follow-up analysis of Axicabtagene Ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood 143(6):496\u2013506. https:\/\/doi.org\/10.1182\/blood.2023021243","journal-title":"Blood"},{"issue":"1","key":"6428_CR11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med 380(1):45\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"issue":"19","key":"6428_CR12","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO et al (2023) Five-year follow-up of ZUMA-1 supports the curative potential of Axicabtagene Ciloleucel in refractory large B-cell lymphoma. Blood 141(19):2307\u20132315. https:\/\/doi.org\/10.1182\/blood.2022018893","journal-title":"Blood"},{"issue":"2","key":"6428_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","volume":"28","author":"NH Fowler","year":"2022","unstructured":"Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J et al (2022) Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med 28(2):325\u2013332. https:\/\/doi.org\/10.1038\/s41591-021-01622-0","journal-title":"Nat Med"},{"issue":"7","key":"6428_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1182\/blood.2019000905","volume":"134","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA, Voutsinas JM, Wu Q, Pender BS, Hawkins RM et al (2019) High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood 134(7):636\u2013640. https:\/\/doi.org\/10.1182\/blood.2019000905","journal-title":"Blood"},{"issue":"26","key":"6428_CR15","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med 377(26):2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"issue":"1","key":"6428_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S et al (2018) CD22-targeted CAR T cells induce remission in B-ALL that is Naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 24(1):20\u201328. https:\/\/doi.org\/10.1038\/nm.4441","journal-title":"Nat Med"},{"issue":"9","key":"6428_CR17","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","volume":"9","author":"G Wei","year":"2021","unstructured":"Wei G, Zhang Y, Zhao H et al (2021) CD19\/CD22 Dual-Targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: A safety and efficacy study. Cancer Immunol Res 9(9):1061\u20131070. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0675","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"6428_CR18","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"NN Shah","year":"2020","unstructured":"Shah NN, Johnson BD, Schneider D et al (2020) Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med 26(10):1569\u20131575. https:\/\/doi.org\/10.1038\/s41591-020-1081-3","journal-title":"Nat Med"},{"issue":"26","key":"6428_CR19","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","volume":"139","author":"J Gauthier","year":"2022","unstructured":"Gauthier J, Gazeau N, Hirayama AV, Hill JA, Wu V, Cearley A et al (2022) Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood 139(26):3722\u20133731. https:\/\/doi.org\/10.1182\/blood.2021014497","journal-title":"Blood"},{"issue":"23","key":"6428_CR20","doi-asserted-by":"publisher","first-page":"6073","DOI":"10.3390\/cancers13236073","volume":"13","author":"A Nydegger","year":"2021","unstructured":"Nydegger A, Novak U, Kronig MN, Legros M, Zeerleder S, Banz Y et al (2021) Transformed lymphoma is associated with a favorable response to CAR-T-Cell treatment in DLBCL patients. Cancers (Basel) 13(23):6073 Published 2021 Dec 2. https:\/\/doi.org\/10.3390\/cancers13236073","journal-title":"Cancers (Basel)"},{"issue":"2","key":"6428_CR21","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","volume":"24","author":"IS Lossos","year":"2011","unstructured":"Lossos IS, Gascoyne RD (2011) Transformation of follicular lymphoma. Best Pract Res Clin Haematol 24(2):147\u2013163. https:\/\/doi.org\/10.1016\/j.beha.2011.02.006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"4","key":"6428_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/hon.2975","volume":"40","author":"T Wang","year":"2022","unstructured":"Wang T, Xu L, Gao L, Tang G, Chen L, Chen J et al (2022) Chimeric antigen receptor T-cell therapy combined with autologous stem cell transplantation improved progression-free survival of relapsed or refractory diffuse large B-cell lymphoma patients: A single-center, retrospective, cohort study. Hematol Oncol 40(4):637\u2013644. https:\/\/doi.org\/10.1002\/hon.2975","journal-title":"Hematol Oncol"},{"issue":"6","key":"6428_CR23","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, Yu W, Dotti G, Yvon ES, Christo SN, Hayball JD et al (2016) GD2-specific CAR T cells undergo potent activation and deletion following antigen encounter but can be protected from activation-induced cell death by PD-1 Blockade. Mol Ther 24(6):1135\u20131149. https:\/\/doi.org\/10.1038\/mt.2016.63","journal-title":"Mol Ther"},{"issue":"20","key":"6428_CR24","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1182\/blood.2022018598","volume":"141","author":"C Roddie","year":"2023","unstructured":"Roddie C, Lekakis LJ, Marzolini MAV et al (2023) Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma. Blood 141(20):2470\u20132482. https:\/\/doi.org\/10.1182\/blood.2022018598","journal-title":"Blood"},{"key":"6428_CR25","doi-asserted-by":"publisher","first-page":"1072192","DOI":"10.3389\/fmed.2022.1072192","volume":"9","author":"L Castagna","year":"2022","unstructured":"Castagna L, Bono R, Tringali S, Sapienza G, Santoro A, Indovina A et al (2022) The place of allogeneic stem cell transplantation in aggressive B-cell non-Hodgkin lymphoma in the era of CAR-T-cell therapy. Front Med (Lausanne) 9:1072192 Published 2022 Dec 6. https:\/\/doi.org\/10.3389\/fmed.2022.1072192","journal-title":"Front Med (Lausanne)"},{"issue":"20","key":"6428_CR26","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1182\/bloodadvances.2019000593","volume":"3","author":"M Shadman","year":"2019","unstructured":"Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A et al (2019) Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Adv 3(20):3062\u20133069. https:\/\/doi.org\/10.1182\/bloodadvances.2019000593","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06428-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06428-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:01:03Z","timestamp":1753171263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06428-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6428"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06428-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5639896\/v1","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prior written informed consent was provided by the patients to participate in the study and offer data for future publication. The study was conducted in accordance with Declaration of Helsinki principles and approved by the Ethics Review Board of the First Affiliated Hospital of Soochow University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}